Lanthanum Carbonate (BAY77-1931)
DrugBAY77-1931 750mg, in the morning, day and evening
NCT Number: NCT00767637
To measure lanthanum concentrations in bone in patients with hyperphosphatemia receiving dialysis
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Phase 2
Isesaki, Gunma, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
BAY77-1931 750mg, in the morning, day and evening
Time frame: Every 2 weeks
Time frame: Every 2 weeks
Time frame: Every 2 weeks
Time frame: Every 2 weeks
Time frame: Every 2 weeks
Time frame: Every 2 weeks
Bayer
Industry
Open Label, Non-controlled Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone in Patients With Hyperphosphatemia Receiving Dialysis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00506441
Chronic Disease, Chronic Kidney Disease
Glendale, Arizona, United States
View Trial DetailsNCT00772382
Chronic Disease, Chronic Kidney Disease
Los Angeles, California, United States
View Trial DetailsNCT00542386
Chronic Disease, Chronic Kidney Disease
Ajka, Hungary
View Trial DetailsNCT00542815
Chronic Disease, Chronic Kidney Disease
Graz, Austria
View Trial Details